Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Aims to become India’s leading cancer testing company
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Subscribe To Our Newsletter & Stay Updated
